This approach allows the digestive system to adapt, particularly important given the already altered gut motility from GLP-1 medications
Shared decision-making : If considering offlabel or prevention use, open discussion of uncertain benefit, possible side effects, cost, monitoring is essential
Its small-molecule structure allows for consistent absorption regardless of stomach contents
Clinical trials have generally shown higher weight loss percentages with this dual approach
NICE Technology Appraisal 875 (Wegovy) and TA664 (Saxenda) recommend these treatments within specialist tier 3 or 4 weight management services for adults with a BMI of 35 kg/m or above (or 32.5 kg/m or above for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds), with weight-related comorbidities
While usually mild and clinically benign, this change deserves attentionespecially in those with heart rhythm disorders or other cardiovascular risk factors